DOW JONES27,081.36-879.44 -3.15%
S&P 5003,128.21-97.68 -3.03%
NASDAQ8,965.61-255.67 -2.77%

Mizuho Initiates Coverage On Sage Therapeutics with Neutral Rating, Announces $69 Price Target

Mizuho analyst Vamil Divan initiates coverage on Sage Therapeutics (NASDAQ:SAGE) with a Neutral rating and a $69 price target.

Benzinga · 02/06/2020 10:19

Mizuho analyst Vamil Divan initiates coverage on Sage Therapeutics (NASDAQ:SAGE) with a Neutral rating and a $69 price target.